Table 2 Characteristics of the participants included in Phase II.

From: Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs

Characteristics

Group A (n = 25)

Group B (n = 24)

p-value

Female, n (%)

15 (60.0)

13 (54.2)

0.680

Age (years), mean ± SD

42.0 ± 14.1

51.8 ± 13.2

0.015

Type of IBD, n (%)

 UC

4 (16.0)

6 (25.0)

0.496

 CD

21 (84.0)

18 (75.0)

0.496

Extent of UC, n (%) (n = 10)

 Proctitis

0 (0.0)

1 (16.7)

1.000

 Left-sided colitis

2 (50.0)

3 (50.0)

1.000

 Extensive colitis

2 (50.0)

2 (33.3)

1.000

Extent of CD, n (%) (n = 39)

 Ileocolonic [L3]

8 (38.1)

10 (55.6)

0.276

 Terminal ileum [L1]

10 (47.6)

5 (27.8)

0.204

 Colonic [L2]

1 (4.8)

1 (5.6)

1.000

 Ileocolonic [L3] + Upper disease [L4]

2 (9.5)

1 (5.6)

1.000

 Terminal ileum [L1] + Upper disease [L4]

0 (0.0)

1 (5.6)

0.462

CD behaviour, n (%) (n = 39)

 Inflammatory

11 (52.4)

12 (66.7)

0.366

 Stricturing

9 (42.9)

3 (16.7)

0.096

 Penetrating

1 (4.8)

2 (11.1)

0.586

 Stricturing + Penetrating

0 (0.0)

1 (5.6)

0.462

  1. p-values in bold format indicate statistical significance (p < 0.05).
  2. CD Crohn’s disease, IBD inflammatory bowel disease, UC ulcerative colitis.
  3. *The Chi-square test or Fisher’s test was used for the qualitative variables, and quantitative variables t-student or Mann–Whitney U test, as appropriate.
Back to article page